Stephen Gately Discusses Precision Medicine in Applied Clinical Trials

June 22, 2018

Cancer is now classified not only by the organ of origin, but by genomic and proteomic profiling.

These “omic” contexts allow drug developers to target tailored treatments even to the rarest of cancers. TD2 CEO, Stephen Gately, shares how cancers can be a rare cancers when you consider their various molecular defects, and how drug developers can focus development of new medicines against these unique “omic” contexts in a recent article published in Applied Clinical Trials.

“Precision medicine provides physicians with the opportunity to avoid less effective treatments and focus on rationally selected medicines that improve clinical outcomes for patients,” said Gately.

Read more about Gately’s outlook on the future of precision medicine in cancer treatment research in the full article.

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.